SCHEMBL3507152

SCHEMBL3507152

Cc1nccn1-c1cccc(O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.57
CYP2E1 P05181 1/20 0.57
CYP2A6 P11509 1/20 0.57
FGFR1 P11362 1/20 0.47
PIK3CA P42336 1/20 0.46
MTOR P42345 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GRM5 P41594 1/20 0.46
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
OPRD1 P41143 4/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP19A1 P11511 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ICMT O60725 2/20 0.43
OPRM1 P35372 2/20 0.42
HSD17B10 Q99714 1/20 0.42
OPRK1 P41145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30797803 1.00 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6FGFR1PIK3CA
SCHEMBL11929770 0.87 CYP3A4 (0.67) CYP3A4CYP2E1CYP2A6ALDH1A1GRM5
SCHEMBL17166601 0.82 CYP3A4 (0.61) CYP3A4CYP2E1CYP2A6ALDH1A1GRM5
SCHEMBL8695867 0.80 CYP3A4 (0.54) CYP3A4CYP2E1CYP2A6ALDH1A1GRM5
SCHEMBL14498657 0.79 FGFR1 (0.47) CYP3A4FGFR1ALDH1A1OPRD1OPRM1
SCHEMBL62408 0.79 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1GRM5
SCHEMBL16923147 0.79 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6PIK3CAMTOR
SCHEMBL22290749 0.79 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1GRM5
SCHEMBL27399890 0.79 FGFR1 (0.47) CYP3A4FGFR1ALDH1A1OPRD1OPRM1
SCHEMBL11983591 0.79 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111344284-B Compounds useful as inhibitors of isoprene cysteine carboxymethyltransferase 新加坡科技研究局 2024-03-12 CN disclosed
CN-111194215-B Methods and compositions for modulating splicing 斯基霍克疗法公司 2024-03-01 CN disclosed
CN-111499615-B Methods and compositions for modulating splicing 斯基霍克疗法公司 2024-02-02 CN disclosed
US-11834430-B2 Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2023-12-05 US disclosed
US-11834430-B2 Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2023-12-05 US disclosed
US-11834430-B2 Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2023-12-05 US disclosed
CN-114269922-A Methods for modulating splicing 斯基霍克疗法公司 2022-04-01 CN disclosed
US-20210130317-A1 Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2021-05-06 US disclosed
US-20210130317-A1 Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2021-05-06 US disclosed
EP-3681878-A1 COMPOUNDS USEFUL AS INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE Agency for Science, Technology and Research (SG) 2020-07-22 EP disclosed
WO-2019054944-A1 COMPOUNDS USEFUL AS INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-03-21 WO disclosed
WO-2013054338-A1 2-THIO-IMIDAZOLE DERIVATIVES AS TGR5 MODULATORS CADILA HEALTHCARE LIMITED (IN) 2013-04-18 WO disclosed
US-20100216788-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 US disclosed
EP-1957495-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-08-20 EP disclosed
WO-2007064045-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-07 WO disclosed
US-5273993-A Antiarthritic agents; osteoporosis A. H. ROBINS COMPANY, INCORPORATED (US) 1993-12-28 US disclosed
US-5194446-A Antiarthritic agents A. H. ROBINS COMPANY, INCORPORATED (US) 1993-03-16 US disclosed
US-5192785-A Sulfamates as antiglaucoma agents A. H. ROBINS COMPANY, INCORPORATED (US) 1993-03-09 US disclosed
US-5025031-A Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants A. H. ROBINS CO., INC. (US) 1991-06-18 US disclosed
EP-0403185-A2 Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals A.H. ROBINS COMPANY, INCORPORATED (US) 1990-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130317-A1 Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase ICMT, INMT, BHMT CYP3A4 859/4885CYP2E1 1007/4885CYP2A6 1209/4885
US-20100216788-A1 FUSED HETEROCYCLIC COMPOUND GRK6, FGFR1, PTK6 CYP3A4 692/4885CYP2E1 1499/4885CYP2A6 28/4885
US-11834430-B2 Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase ICMT, INMT, BHMT CYP3A4 859/4885CYP2E1 1007/4885CYP2A6 1209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.